

Shelley Zieroth

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5337062/shelley-zieroth-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42 papers	1,057 citations	16 h-index	32 g-index
45 ext. papers	1,611 ext. citations	3.8 avg, IF	4.01 L-index

#	Paper	IF	Citations
42	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.. <i>Nature Medicine</i> , 2022 ,	50.5	27
41	Polymorphic Ventricular Tachycardia Detected With a Smartwatch.. <i>CJC Open</i> , 2022 , 4, 424-427	2	0
40	Adequate Decongestion Is Still the Question in Heart Failure. <i>Cardiology</i> , 2021 , 146, 60-62	1.6	
39	Establishing a Cardiac Amyloidosis Clinic: A Practical Primer for Cardiologists. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 674-678	3.8	0
38	National Trends of Gender Disparity in Canadian Cardiovascular Society Guideline Authors, 2001-2020.. <i>CJC Open</i> , 2021 , 3, S12-S18	2	3
37	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 531-546	3.8	48
36	Hyperkalaemia in Heart Failure. <i>Cardiac Failure Review</i> , 2021 , 7, e10	4.2	1
35	Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?. <i>Current Opinion in Cardiology</i> , 2021 , 36, 672-681	2.1	1
34	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. <i>International Journal of Cardiology</i> , 2021 , 327, 138-145	3.2	12
33	Trends, management and outcomes of acute myocardial infarction in chronic liver disease. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13841	2.9	1
32	Automated E-Counseling for Chronic Heart Failure: CHF-CePPORT Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e007073	7.6	0
31	Long COVID-19: A Primer for Cardiovascular Health Professionals, on Behalf of the CCS Rapid Response Team. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 1260-1262	3.8	4
30	Characteristics of Clinicians Are Associated With Their Beliefs About ICD Deactivation: Insight From the DECIDE-HF Study. <i>CJC Open</i> , 2021 , 3, 994-1001	2	0
29	Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats. <i>Molecules</i> , 2021 , 26,	4.8	1
28	Are post-hoc analyses on subgroups sufficient to support new treatment algorithms of heart failure? The case of SGLT2 inhibitors associated with sacubitril/valsartan. <i>Cardiology</i> , 2021 ,	1.6	1
27	Optimizing Access to Heart Failure Care in Canada During the COVID-19 Pandemic. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 1148-1151	3.8	11
26	Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 335-356	3.8	17

25	The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. <i>CJC Open</i> , 2020 , 2, 151-160 ²	4
24	Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 322-334	3.8 27
23	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 159-169 ⁸	50
22	The Hospital Frailty Risk Score and its association with in-hospital mortality, cost, length of stay and discharge location in patients with heart failure short running title: Frailty and outcomes in heart failure. <i>International Journal of Cardiology</i> , 2020 , 300, 184-190	3.2 23
21	HEARTBIT: A Transcriptomic Signature for Excluding Acute Cellular Rejection in Adult Heart Allograft Patients. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 1217-1227	3.8 7
20	Hyperkalemia in heart failure. <i>Current Opinion in Cardiology</i> , 2020 , 35, 150-155	2.1 8
19	Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada. <i>CJC Open</i> , 2020 , 2, 321-327	2 3
18	Sex, Gender, and Equity in Cardiovascular Medicine, Surgery, and Science in Canada Challenges, Successes, and Opportunities for Change. <i>CJC Open</i> , 2020 , 2, 522-529	2 5
17	Comparative effectiveness of the different components of care provided in heart failure clinics-protocol for a systematic review and network meta-analysis. <i>Systematic Reviews</i> , 2019 , 8, 40	3 4
16	The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3 75
15	Relation of Increasing QRS Duration Over Time and Cardiovascular Events in Outpatients With Heart Failure. <i>American Journal of Cardiology</i> , 2019 , 124, 1907-1911	3 2
14	Are the cardioprotective effects of the phytoestrogen resveratrol sex-dependent?. <i>Canadian Journal of Physiology and Pharmacology</i> , 2019 , 97, 503-514	2.4 9
13	Multicenter evaluation of a national organ sharing policy for highly sensitized patients listed for heart transplantation in Canada. <i>Journal of Heart and Lung Transplantation</i> , 2017 , 36, 491-498	5.8 16
12	Primary Percutaneous Coronary Intervention As Treatment for ST-Elevation Myocardial Infarction in a Centenarian: Choosing Carefully. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1066.e1-1066.e3	3.8 2
11	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1342-1433	3.8 330
10	Barriers to Goals of Care Discussions With Patients Who Have Advanced Heart Failure: Results of a Multicenter Survey of Hospital-Based Cardiology Clinicians. <i>Journal of Cardiac Failure</i> , 2017 , 23, 786-793 ³	21
9	Peripartum Cardiomyopathy Characteristics and Outcomes in Canadian Aboriginal and Non-Aboriginal Women. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 471-477	3.8 3
8	The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 296-310	3.8 65

7	Diagnosis of Left Ventricular Assist Device Outflow Graft Obstruction Using Intravascular Ultrasound. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	7
6	Resveratrol is equipotent to perindopril in attenuating post-infarct cardiac remodeling and contractile dysfunction in rats. <i>Journal of Nutritional Biochemistry</i> , 2016 , 28, 155-63	6.3	21
5	An overview of the efficacy of resveratrol in the management of ischemic heart disease. <i>Annals of the New York Academy of Sciences</i> , 2015 , 1348, 55-67	6.5	33
4	The Urea-to-Creatinine Ratio Is Predictive of Worsening Kidney Function in Ambulatory Heart Failure Patients. <i>Journal of Cardiac Failure</i> , 2015 , 21, 412-418	3.3	13
3	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 3-16	3.8	77
2	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 249-63	3.8	36
1	Potential of resveratrol in the treatment of heart failure. <i>Life Sciences</i> , 2014 , 95, 63-71	6.8	72